home / stock / huma / huma news

HUMA News and Press, Humacyte Inc. From 05/12/23

Stock Information
Company Name: Humacyte Inc.
Stock Symbol: HUMA
Market: NASDAQ
Website: humacyte.com
Menu
HUMA HUMA Quote HUMA Short HUMA News HUMA Articles HUMA Message Board
Get HUMA Alerts

News, Short Squeeze, Breakout and More Instantly...
HUMA - Humacyte and Oberland Capital Announce Funding Arrangement Totaling Up to $160 Million

- $40 million upfront, $20 million upon FDA acceptance of HAV BLA in vascular trauma, $40 million upon FDA approval of HAV in vascular trauma, $50 million upon achievement of certain sales milestones, and $10 million equity option - - Proceeds to support planned development and commerci...
HUMA - Humacyte Announces Publication in Lancet Regional Health - Europe Presenting Use of Human Acellular Vessel(TM) (HAV(TM)) to Treat Vascular Injuries in Ukraine

First regenerative medicine technology used in battlefield trauma Ukrainian surgeons trained on HAV procedures over video conferencing DURHAM, N.C., May 09, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universal...

HUMA - Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 12, 2023

DURHAM, N.C., May 05, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, will release its financial results for the first quarter ended March 31, 2023, on Friday...

HUMA - Humacyte's Human Acellular Vessel(TM) (HAV(TM)) Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for Urgent Arterial Repair Following Vascular Trauma

HAV granted second RMAT designation by the FDA RMAT will support Humacyte’s lead indication in Vascular Trauma DURHAM, N.C., May 04, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioeng...
HUMA - Humacyte to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

DURHAM, N.C., April 28, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Execut...

HUMA - Humacyte, JDRF Collaborating to Develop Insulin-Producing Biovascular Pancreas to Treat Type 1 Diabetes

NEW YORK, N.Y. and DURHAM, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a biotechnology company pioneering the development and manufacturing of off-the-shelf, universally implantable bioengineered human tissues and organ systems, and JDRF International (JDRF), the leadi...

HUMA - Humacyte Announces Publication of Preclinical Study Comparing Human Acellular Vessel(TM) (HAV(TM)) to Expanded Polytetrafluoroethylene (ePTFE) Graft in Vascular Trauma

Results published in Journal of Trauma and Acute Care Surgery Company also provides update on enrollment progress in Phase 2/3 vascular trauma trial DURHAM, N.C., April 18, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company deve...
HUMA - Humacyte Completes Enrollment in Phase 3 Trial of Human Acellular Vessel(TM) (HAV(TM)) for Hemodialysis Access in End-Stage Renal Disease Patients

DURHAM, N.C., April 11, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced it has completed enrollment of a Phase 3 trial in hemodialysis access....

HUMA - Humacyte, Inc. (HUMA) Q4 2022 Earnings Call Transcript

2023-03-27 14:46:10 ET Humacyte, Inc. (HUMA) Q4 2022 Earnings Conference Call March 24, 2023 8:00 AM ET Company Participants Lauren Marek - LifeSci Advisors, Investor Relations Laura Niklason - President and Chief Executive Officer Dale Sander - Chief Financial O...

HUMA - Humacyte stock dips after Q4 sees net loss, no grant revenue

2023-03-24 11:55:56 ET Humacyte ( NASDAQ: HUMA ) stock fell ~8% on Friday after the company's Q4 results. The company's net loss per share was -$0.04, compared to net income per share of $0.41 in Q4 2021. Humacyte did not have Grant revenue in Q4 compared to $177K ...
Previous 10 Next 10